Lasix was the center of the conversation at the Oct. 28 Kentucky Drug and Research Council meeting, and the most controversial item of the day—phasing out Lasix in 2-year-olds and stakes races in Kentucky—was voted down by the advisory committee.
Lasix was the center of the conversation at the Oct. 28 Kentucky Drug and Research Council meeting, and the most controversial item of the day—phasing out Lasix in 2-year-olds and stakes races in Kentucky—was voted down by the advisory committee.